1Simon K, Rotter K, Zalewska M, et al. HBV-DNA level in blood serum as a predictor of good response to therapy with interferon-alpha-2b of patients with chronic hepatitis B. Med Sci Monit,2000,6:971-975.
2Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology,2001,34: 1021-1026.
3Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology, 1998,114: 988-995.
4Heijtink RA, Janssen HL, Hop WC. Interferon-alpha therapy for chronic hepatitis B: early response related to pre-treatment changes in viral replication. J Med Virol,2001,63:217-219.
5Perrilloa RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdral for the treatment of chronic hepatitis B. N Engl J Med, 1990,323:295-301.
6Nafa S, Ahmed S, Tavan D, et al. Early detectioin of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology, 2000,32:1078-1088.
7Wolters LM, Van-Nunen AB, Niesters HG, et al. Contrasting patterns of response to lamivudine monotherapy in chronic hepatitis B patients. Scand J Gastroenterol,2000,232: Suppl 74-78.
8Puchhanuner-Stocki E, Mandl CW, Kletzmayr J, et al. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis, 2000,181: 2063-2066.
9Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviralresistant human hepatitis B virus mutations in the polymerase region.Hepatology,2001,33: 751-757.
10Mazzaferro V, Brunetto MR, Pasquali M, et al. Preoperative serum levels of wild-type and hepatitis B e antigen-negative hepatitis B virus (HBV) and graft infection after liver transplantation for HBV-related hepatocellular carcinoma. J Viral Hepatitis, 1997,4: 235-242.
同被引文献24
1骆抗先.乙型肝炎基础和临床（第2版）[M].北京:人民卫生出版社,2001.415-435.
2Merican l,Guan R,Amarapuka D,et al. SPECIAL REPORT:Chronic hepatitis B virus infection in Asian countries[J].Journal of Gastroenterology and Hepatology, 2000,15 : 1356.
3Crowley SJ, Tognarini D. Desmond PV, et al. Cost -- effectiveness analysis of lamivudine for the treatment of chronic hepatitis B[J]. Pharmacoeconomics, 2000.17 (5) : 409.
4Zar S, Kumar D, Benson MJ. Food hypersensitivity and irritable bowel syndrome[J]. Alimentary Pharmacology&Therapeutics,2001,15(4) : 439.
5Groeneweg M, Moerland W. Quero JC, et al. Screening of subclinical hepatic encephalopathy[J].J Hepatol, 2000,32 (5) : 748.
6Park CK, Park SY, Kim ES, et al. Assessment of quality of life and associated factor patients with chronic viral liver disease[J]. Taehan Kan Hakhoe Chi,2003,9(3) : 212.
7Ian M, Gralnek MD, Ron D, et al. Development and evaluation of the liver disease quality of life instrument in persons with advaneed, chronic liver disease the LDQOL 1.0[J]. The Atnerican .Journal of Gastroenterology, 2000,95 ( 12 ) : 3552.
8Giulio Marchesini, Giampaolo Bianhchi, Piero Amodio, et al.Factors associated with poor health--related quality of life of patients with cirrhosis[J]. Gastroenterology, 2001,120 : 170.
9Younossi ZM, Boparai N, Price LL, et al. Assessment of utilities and health--related quality of life in patients with chronic liver disease [J]. The American Journal of Gastroenterology.2001,96(2) : 579.
10Liaw YF · Resuts of lamivudine triais in Asia[J].Hepatol,2003,39:111-115.
